EVOK - Evoke Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4900
-0.0500 (-3.25%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.5400
Open1.5600
Bid0.0000 x 1100
Ask0.0000 x 1200
Day's Range1.4700 - 1.5600
52 Week Range0.5000 - 3.2600
Volume271,099
Avg. Volume317,896
Market Cap36.106M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-0.3660
Earnings DateAug 07, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • GlobeNewswire

    Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™

    EVERSANA to commercialize and distribute Gimoti in the U.S. SOLANA BEACH, Calif. and CHICAGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced a collaboration to utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Gimoti™ in the United States (U.S.). Gimoti is Evoke’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

  • Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
    Zacks

    Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

    The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

  • GlobeNewswire

    FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s resubmission of its 505(b)(2) New Drug Application (NDA) for Gimoti™, the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

  • GlobeNewswire

    Evoke Resubmits Gimoti™ New Drug Application to FDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Gimoti™, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. The NDA for Gimoti was resubmitted based on feedback received during the Type A meeting with FDA in July 2019.

  • GlobeNewswire

    Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement under Nasdaq’s Marketplace Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Accordingly, Nasdaq considers the matter closed. Gastroparesis is a debilitating, episodic condition that disproportionately affects adult women and is characterized by slow or delayed gastric emptying of the stomach’s contents after meals, often resulting in flares of symptoms that include nausea, vomiting, abdominal pain and bloating.

  • What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register?

    A look at the shareholders of Evoke Pharma, Inc. (NASDAQ:EVOK) can tell us which group is most powerful. Institutions...

  • GlobeNewswire

    Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has been granted an additional 180-day grace period to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550(a)(2). In accordance with the rule, the Company was eligible for the additional compliance period because it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement.

  • GlobeNewswire

    Evoke Pharma Reports Third Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Nov. 07, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.

  • Foamix Initiates Phase II Study on Acne Combination Foam
    Zacks

    Foamix Initiates Phase II Study on Acne Combination Foam

    Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

  • When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Come Back To Market?
    Simply Wall St.

    When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Come Back To Market?

    Trailing twelve-month data shows us that Evoke Pharma, Inc.'s (NASDAQ:EVOK) earnings loss has accumulated to -US$7.4m...

  • Zynerba Releases Data on Epilepsy Candidate, Stock Down
    Zacks

    Zynerba Releases Data on Epilepsy Candidate, Stock Down

    Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

  • GlobeNewswire

    Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti (metoclopramide nasal spray) with its partner Thermo Fisher Scientific, a leading global contract development and manufacturing organization that specializes in the preparation, fill and finish of nasal spray products. Evoke plans to collect Chemistry, Manufacturing and Controls (CMC) data from these registration batches, which were requested in the complete response letter (CRL) from the U.S. Food and Drug Administration (FDA).

  • GlobeNewswire

    Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Aug. 08, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.

  • Benzinga

    Biotech Stock On The Radar: Evoke Pharma Sets Date With FDA

    After wallowing in penny stock territory until mid-July, the stock has broken the downtrend seen since early March and is experiencing some upward momentum. The company bought the rights to the investigational asset from Questcor Pharma in 2007 by paying $650,000 upfront and an additional $500,000 in May 2014 as a milestone payment. It is being evaluated as a treatment option for relieving symptoms in adult women with acute and recurrent diabetic gastroparesis.

  • Is Evoke Pharma, Inc. (NASDAQ:EVOK) A Volatile Stock?
    Simply Wall St.

    Is Evoke Pharma, Inc. (NASDAQ:EVOK) A Volatile Stock?

    If you're interested in Evoke Pharma, Inc. (NASDAQ:EVOK), then you might want to consider its beta (a measure of share...

  • GlobeNewswire

    Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted a type A meeting request and meeting package to the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) dated April 1, 2019 regarding Evoke’s New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. During the meeting, Evoke plans to discuss the Company’s strategy to address these issues as well as any other matters pertaining to the steps required for the resubmission of the Gimoti NDA. “We have been working diligently to prepare the meeting package required at the time a type A meeting request is submitted to FDA.

  • GlobeNewswire

    Evoke Pharma Reports First Quarter 2019 Financial Results

    Projected cash runway extended to first quarter 2020 SOLANA BEACH, Calif., May 08, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on.

  • Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
    Zacks

    Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

    During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

  • Investors Who Bought Evoke Pharma (NASDAQ:EVOK) Shares Five Years Ago Are Now Down 92%
    Simply Wall St.

    Investors Who Bought Evoke Pharma (NASDAQ:EVOK) Shares Five Years Ago Are Now Down 92%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We're definitely into long term investing, but some companies are simply bad investments over any ti...

  • Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
    Zacks

    Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

    Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

  • Benzinga

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • GlobeNewswire

    Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its 505(b)(2) New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. The CRL, which cites fewer issues than the recent multidisciplinary review letter, states that FDA has determined it cannot approve the NDA in its present form and provides recommendations to address the two remaining approvability issues in an NDA resubmission.

  • Benzinga

    Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

    Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally ...

  • GlobeNewswire

    Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S. Food and Drug Administration’s (FDA) multi-disciplinary review (DR) letter that was received on March 1, 2019 in association with the Gimoti 505(b)(2) New Drug Application (NDA). In addition, the Company requested a meeting with the FDA prior to the Prescription Drug User Fee Act (PDUFA) action date of April 1, 2019. The purpose of this meeting is to obtain FDA’s feedback on the Company’s responses.

  • GlobeNewswire

    Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

    Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration (FDA) for Gimoti™ 505(b)(2) New Drug Application (NDA)April 1, 2019 Prescription.